Abstract: The present disclosure generally relates to methods and apparatus for heating a substrate as well as a slot management method for a thermal treatment chamber that in one embodiment includes providing a first substrate to a first slot of a carrier in the thermal treatment chamber via a transfer opening formed in the thermal treatment chamber, the first substrate having a specified anneal time, heating the substrate, moving the carrier to a lowermost position in the thermal treatment chamber using an elevator mechanism coupled to the carrier, and moving the carrier such that the first slot is in a position adjacent to the transfer opening using the elevator mechanism within a carrier transfer time period and transferring the first substrate out of the thermal treatment chamber at a determined time period for anneal.

Abstract: The present disclosure generally relates to methods and apparatus for heating a substrate as well as a slot management method for a thermal treatment chamber that in one embodiment includes providing a first substrate to a first slot of a carrier in the thermal treatment chamber via a transfer opening formed in the thermal treatment chamber, the first substrate having a specified anneal time, heating the substrate, moving the carrier to a lowermost position in the thermal treatment chamber using an elevator mechanism coupled to the carrier, and moving the carrier such that the first slot is in a position adjacent to the transfer opening using the elevator mechanism within a carrier transfer time period and transferring the first substrate out of the thermal treatment chamber at a determined time period for anneal.

Abstract: Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.

Abstract: Implementations described herein generally relate to a method and apparatus for processing substrates in a processing system. The method includes identifying, in a buffer chamber coupled to a transfer chamber of a processing system, a first substrate that has been in the buffer chamber longer than a predetermined duration and identifying a first destination chamber of the processing system for the first substrate. After identifying the first substrate, a buffer chamber time-out operation is performed. The buffer time out operation includes suspending movement of substrates from a load lock chamber to the transfer chamber and removing the first substrate from the buffer chamber.

Abstract: Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.

Abstract: Embodiments of the present invention provide systems, apparatus, and methods for protecting processing recipes. Embodiments include a remote host external to an electronic device manufacturing facility, the remote host including a recipe editor adapted to allow creating of a protected processing recipe; a material control system (MCS) within the electronic device manufacturing facility and operable to communicate with the remote host; a master controller (MC) in communication with the MCS; and at least one processing tool in communication with the MC and including volatile memory adapted to store the protected processing recipe for execution by the processing tool. The remote host is operable to transfer the protected processing recipe to the volatile memory of the processing tool without allowing the protected processing recipe to be accessible by a user within the electronic device manufacturing facility. Numerous additional aspects are disclosed.

Abstract: The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.

Abstract: Systems, methods, and apparatus are provided for operating a cluster tool including receiving recipe time data; receiving transfer time data; receiving process programs and associated substrate lots wherein the process programs include a plurality of sequences; determining cluster tool chambers associated with sequences that are bottleneck sequences; setting equipment constant values for components of the cluster tool to implement transfer priorities wherein the chambers associated with bottleneck sequences are given highest priority; executing a next sequence based on the transfer priorities; and repeating the determining, setting and executing for each remaining sequence. Numerous additional aspects are disclosed.

Abstract: The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).

Abstract: Systems, methods, and apparatus are provided for operating a cluster tool including receiving recipe time data; receiving transfer time data; receiving process programs and associated substrate lots wherein the process programs include a plurality of sequences; determining cluster tool chambers associated with sequences that are bottleneck sequences; setting equipment constant values for components of the cluster tool to implement transfer priorities wherein the chambers associated with bottleneck sequences are given highest priority; executing a next sequence based on the transfer priorities; and repeating the determining, setting and executing for each remaining sequence. Numerous additional aspects are disclosed.

Abstract: A method and system for a mainframe premove for a cluster tool is described herein. In one embodiment, the state of a process chamber which is to be used to run a process is obtained. A determination is made of whether the state of the process chamber indicates an almost ready state. A prepare command is sent to a transfer module if the state of the process chamber indicates the almost ready state. A transfer command is sent to the process chamber if the state of the process chamber indicates the almost ready state.

Abstract: Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13R?2 antagonist, and/or a AP-I antagonist.

Abstract: Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-?B decoy polynucleotide.

Abstract: The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-? therapy. The compositions of the present invention provide vectors containing TGF-? under the control of an inducible promoter. In particularly preferred embodiments, the present invention provides regulated plasmid constructs capable of inducing TGF-? production. In preferred embodiments, the methods of the present invention utilize the vectors described for assaying the expression of a gene in a cell. In some preferred embodiments, the methods of the present invention utilize the administration of TGF-? containing vectors to treat IBD. In alternative preferred embodiments, the present invention provides methods and compositions for the induction of high-level interleukin (e.g., IL-10) production.

Abstract: The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.

Abstract: Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-?B decoy polynucleotide.

Abstract: The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-? therapy. The compositions of the present invention provide vectors containing TGF-? under the control of an inducible promoter. In particularly preferred embodiments, the present invention provides regulated plasmid constructs capable of inducing TGF-? production. In preferred embodiments, the methods of the present invention utilize the vectors described for assaying the expression of a gene in a cell. In some preferred embodiments, the methods of the present invention utilize the administration of TGF-? containing vectors to treat IBD. In alternative preferred embodiments, the present invention provides methods and compositions for the induction of high-level interleukin (e.g., IL-10) production.

Abstract: The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the inflammatory response of the inflammatory bowel disease.

Abstract: The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the inflammatory response of the inflammatory bowel disease.